MX2011011871A - Formulacion intravenosa con cocristales solubles en agua de acido acetilisalicilico y teanina. - Google Patents
Formulacion intravenosa con cocristales solubles en agua de acido acetilisalicilico y teanina.Info
- Publication number
- MX2011011871A MX2011011871A MX2011011871A MX2011011871A MX2011011871A MX 2011011871 A MX2011011871 A MX 2011011871A MX 2011011871 A MX2011011871 A MX 2011011871A MX 2011011871 A MX2011011871 A MX 2011011871A MX 2011011871 A MX2011011871 A MX 2011011871A
- Authority
- MX
- Mexico
- Prior art keywords
- acetylsalicylic acid
- theanine
- water
- soluble
- intravenous formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C231/00—Preparation of carboxylic acid amides
- C07C231/22—Separation; Purification; Stabilisation; Use of additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
Una composición de co-cristal de aspirina-teanina soluble en agua que incluye una cantidad de ácido acetilsalicílico y una cantidad de un enantiómero de teanina asociada con la cantidad de ácido acetilsalicílico. La composición puede crearse por un método que incluye las etapas de: (i) proporcionar una cantidad de ácido acetilsalicílico; (ii) agregar una cantidad de un enantiómero de teanina a la cantidad de ácido acetilsalicílico para formar una mezcla que comprende la cantidad de ácido acetilsalicílico y el enantiómero de teanina; (iii) humectar la mezcla y (iv) moler la mezcla por una longitud de tiempo suficiente para producir una masa cristalina seca. La composición de co-cristal soluble en agua es apropiada para administración intravenosa, preferentemente en humanos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/437,735 US8173625B2 (en) | 2009-05-08 | 2009-05-08 | Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine |
PCT/US2009/048275 WO2010128977A1 (en) | 2009-05-08 | 2009-06-23 | Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011011871A true MX2011011871A (es) | 2012-03-06 |
Family
ID=43050309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011011871A MX2011011871A (es) | 2009-05-08 | 2009-06-23 | Formulacion intravenosa con cocristales solubles en agua de acido acetilisalicilico y teanina. |
Country Status (13)
Country | Link |
---|---|
US (11) | US8173625B2 (es) |
EP (1) | EP2427196B1 (es) |
JP (1) | JP5568127B2 (es) |
KR (1) | KR101603368B1 (es) |
CN (1) | CN102421438B (es) |
CA (1) | CA2760555C (es) |
EA (1) | EA022058B1 (es) |
HK (1) | HK1164162A1 (es) |
IL (1) | IL215922A (es) |
MX (1) | MX2011011871A (es) |
NZ (1) | NZ596200A (es) |
SG (1) | SG175921A1 (es) |
WO (1) | WO2010128977A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173625B2 (en) * | 2009-05-08 | 2012-05-08 | Theaprin Pharmaceuticals Inc. | Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine |
ITMI20120586A1 (it) | 2012-04-11 | 2013-10-12 | Milano Politecnico | Co-cristalli di 3-iodiopropinil butilcarbammato |
GB201311984D0 (en) * | 2013-07-04 | 2013-08-21 | Univ Cardiff | Methods and compounds for preventing or treating osteoarthritis |
RU2539350C1 (ru) * | 2013-12-24 | 2015-01-20 | Федеральное государственное бюджетное учреждение науки Институт химии растворов им. Г.А. Крестова Российской академии наук (ИХР РАН) | Сокристаллическая форма 2-гидроксибензамида с салициловой кислотой |
US10508096B2 (en) | 2014-05-27 | 2019-12-17 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
US9896429B2 (en) | 2014-05-27 | 2018-02-20 | R.J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
WO2015183801A1 (en) | 2014-05-27 | 2015-12-03 | R. J. Reynolds Tobacco Company | Nicotine salts, co-crystals, and salt co-crystal complexes |
US10066056B2 (en) | 2014-06-19 | 2018-09-04 | Sabic Global Technologies B.V. | Brominated cross-linkable polycarbonate compositions |
US9603937B2 (en) * | 2015-03-09 | 2017-03-28 | Theaprin Pharmaceuticals Inc. | Platform drug delivery system utilizing crystal engineering and theanine dissolution |
PL3379952T3 (pl) | 2015-11-25 | 2024-03-18 | R. J. Reynolds Tobacco Company | Kompleksy soli, kokryształów i kokryształów soli nikotyny |
US10376464B2 (en) * | 2015-11-25 | 2019-08-13 | Theaprin Pharmaceuticals Inc. | Characterization of the cocrystal products formed by metoprolol and dabigatran bases with L-theanine |
SI3474858T1 (sl) * | 2016-06-28 | 2022-01-31 | Asamedic As | Dvokomponentni sestavek, ki obsega acetilsalicilno kislino |
US20200101010A1 (en) * | 2017-05-30 | 2020-04-02 | Theaprin Pharmaceuticals, Inc. | Sublingual formulation with water-soluble cocrystals of acetylsalicylic acid with citric acid, sodium bicarbonate, and l-theanine for the treatment of acute myocardial infarction |
WO2019049049A1 (en) | 2017-09-05 | 2019-03-14 | R. J. Reynolds Tobacco Company | SALTS, CO-CRYSTALS, AND CO-CRYSTAL COMPLEXES OF NICOTINE SALTS |
EP3501522A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Compositions comprising acetylsalicylic acid and a phosphate salt |
EP3501523A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Two-component compositions comprising acetyl salicylic acid and a carbonate salt |
EP4146188A1 (en) * | 2020-05-08 | 2023-03-15 | Theaprin Pharmaceuticals Inc. | Cocrystal antioxidants of protocatechuic acid with l-theanine for the treatment of oxidative stress and inflammatory conditions |
CN111870558B (zh) * | 2020-08-17 | 2022-07-12 | 山东华熙海御生物医药有限公司 | 一种抑制透明质酸酶活性的组合物及皮肤护理产品 |
WO2022231998A1 (en) * | 2021-04-27 | 2022-11-03 | Theaprin Pharmaceuticals, Inc. | Compositions comprising cocrystals of acetylsalicylic acid and theanine with tromethamine and methods of use |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5157030A (en) | 1989-08-25 | 1992-10-20 | Alexander Galat | Rapidly soluble aspirin compositions and method |
US5665388A (en) | 1995-11-13 | 1997-09-09 | Health Corporation | Method for preparation of an alkaline and aspirin combination compound |
US5723453A (en) | 1995-11-13 | 1998-03-03 | Health Corporation | Stabilized, water-soluble aspirin composition |
US5776431A (en) | 1997-03-26 | 1998-07-07 | Galat; Alexander | Water-soluble aspirin composition |
US6665388B2 (en) * | 2000-12-20 | 2003-12-16 | Bellsouth Intellectual Property Corporation | System and method for monitoring incoming communications to a telecommunications device |
AU2002310237A1 (en) | 2001-05-31 | 2002-12-09 | Galileo Laboratories, Inc. | Sponge-derived terpenoids and methods of use |
DE10202019A1 (de) * | 2002-01-18 | 2003-07-24 | Bayer Ag | Stabile Salze von o-Acetylsalicylsäure mit basischen Aminosäuren II |
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
WO2005047501A1 (en) * | 2003-02-24 | 2005-05-26 | Johns Hopkins University | Molecular vaccines employing nucleic acid encoding anti-apoptotic proteins |
US20060292225A1 (en) | 2005-06-24 | 2006-12-28 | Felix Arthur M | Water soluble analgesic formulations and methods for production |
MX2008012065A (es) * | 2006-03-23 | 2008-10-07 | Herbalscience Singapore Pte Ltd | Extractos y metodos que comprenden especies de te verde. |
US8173625B2 (en) | 2009-05-08 | 2012-05-08 | Theaprin Pharmaceuticals Inc. | Intravenous formulation with water-soluble cocrystals of acetylsalicylic acid and theanine |
-
2009
- 2009-05-08 US US12/437,735 patent/US8173625B2/en active Active
- 2009-06-23 CN CN200980158968.4A patent/CN102421438B/zh active Active
- 2009-06-23 EA EA201101458A patent/EA022058B1/ru unknown
- 2009-06-23 EP EP09844455.7A patent/EP2427196B1/en active Active
- 2009-06-23 NZ NZ596200A patent/NZ596200A/xx unknown
- 2009-06-23 SG SG2011081825A patent/SG175921A1/en unknown
- 2009-06-23 CA CA2760555A patent/CA2760555C/en active Active
- 2009-06-23 WO PCT/US2009/048275 patent/WO2010128977A1/en active Application Filing
- 2009-06-23 MX MX2011011871A patent/MX2011011871A/es active IP Right Grant
- 2009-06-23 KR KR1020117026470A patent/KR101603368B1/ko active IP Right Grant
- 2009-06-23 JP JP2012509772A patent/JP5568127B2/ja active Active
-
2011
- 2011-10-25 IL IL215922A patent/IL215922A/en active IP Right Grant
-
2012
- 2012-04-05 US US13/440,693 patent/US8304404B2/en active Active
- 2012-05-25 HK HK12105136.0A patent/HK1164162A1/xx unknown
- 2012-09-14 US US13/617,508 patent/US20130012482A1/en not_active Abandoned
-
2013
- 2013-01-02 US US13/732,807 patent/US8476250B2/en active Active
- 2013-08-14 US US13/967,027 patent/US8685948B2/en active Active
-
2014
- 2014-01-31 US US14/169,291 patent/US9289438B2/en active Active
- 2014-02-25 US US14/188,841 patent/US9289439B2/en active Active
- 2014-04-25 US US14/262,281 patent/US20140235594A1/en not_active Abandoned
- 2014-05-21 US US14/283,298 patent/US20140296189A1/en not_active Abandoned
- 2014-06-04 US US14/295,684 patent/US9289440B2/en active Active
- 2014-07-31 US US14/447,800 patent/US20140343021A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011011871A (es) | Formulacion intravenosa con cocristales solubles en agua de acido acetilisalicilico y teanina. | |
BRPI1008396B8 (pt) | composto de sal de tosilato de um derivado de 5-pirazolil-2-piridona, composição farmacêutica, uso e processo para preparação do dito composto | |
BR112014009087A2 (pt) | formulações de etanercept estabilizadas com xilitol | |
MY183588A (en) | New salvianolic acid compound l, preparation method and use thereof | |
WO2012016845A3 (en) | Pharmaceutical formulation comprising a phosphodiesterase inhibitor | |
MX2010010647A (es) | Proceso para preparar formulaciones de dabigatran para administracion oral. | |
WO2012122340A8 (en) | Soluble guanylate cyclase activators | |
HK1138840A1 (en) | Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors | |
MX336810B (es) | Benzoxazepinonas fusionadas como moduladoras de canales ionicos. | |
WO2012116290A3 (en) | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | |
NZ714558A (en) | Formulation comprising a hypolipidemic agent | |
GB201216469D0 (en) | Stabilisation of viral particles | |
MY166797A (en) | Geopolymer activator composition and geopolymer binder, paste and concrete prepared therewith | |
MX2015014336A (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
WO2013028818A8 (en) | Pyrimido- pyridazinone compounds and use thereof | |
NZ600263A (en) | 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof | |
BR112013004455A2 (pt) | composições para fornecimento gástrico de agentes ativos | |
MX348979B (es) | Agente de control de enfermedades de las plantas. | |
WO2009100101A3 (en) | Solid formulation of low melting active compound | |
GEP20135997B (en) | Tricyclic indazole compound, method of their preparation and pharmaceutical composition containing thereof | |
EA201270302A1 (ru) | Безводные формы производных пиридина | |
WO2012112841A3 (en) | [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation | |
TW200833371A (en) | Process for solid formulations | |
CL2010000226A1 (es) | Metodo para retardar la maduracion de un cultivo aplicando una mezcla de una fuente fosforosa, y una fuente de acido giberelico; y metodo para retardar la maduracion de un cultivo incorporando una composicion en un revestimiento. | |
MX2010000693A (es) | Composicion farmaceutica que comprende un compuesto de 11-desoxi-prostaglandina y metodo para establilizar el compuesto. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: ABBVIE INC. |
|
FG | Grant or registration |